adverse events have to be minimized and the therapeutic cardioembolic = 12; small vessel occlusion = 22; other benefits maximized.
determined etiology =three; undetermined etiology = four).
The National Institute of Neurological Disorders and
The mean time to reach emergency was 2.4h (1.15-3.4), Stroke (NINDS) study on the intravenous use of the mean door to CT, 24 min (10-47) and the door to recombinant tissue plasminogen activator (rtPA) within recombinant tissue plasminogen activator (r-tPA) injection, three hours of a an AIS has shown the benefit of this 26.8 min (25-67). The NIHSS scores ranged from 11 to 22
form of treatment.
[1] In order to be effective the protocol (mean = 15.5 ± 2.7). Patients with history of liver or renal for institution of rtPA therapy must be strictly followed.
disease or those on anticoagulants were excluded. The
The evidence for this form of therapy is of Level I.
[2] When PT, aPTT and platelet count were not done. Recombinant all accumulated evidence for rtPA therapy is considered, tissue plasminogen activator was administered at a dosage the relative risk reduction provided by it is 44%, absolute of 0.9 mg/Kg. Results: Thirty-five patients (65%) signifirisk reduction is 13% and the number needed to treat to cantly improved on NIHSS at 48h (≥4 points) (mean change save one person from death or disability is seven.
[3]
= 10; range= 4-17). At one month, 43 (79%) improved on Barthel Index (mean change = 45%). One each developed small frontal lobe hemorrhage and recurrent stroke; one died of aspiration; and eight showed no improvement. Conclusions: Hyperacute thrombolysis was found useful and safe in selected patients with AIS even without the coagulation studies.
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Acute ischemic stroke (AIS) is one area in neurological clinical practice that has probably seen the greatest strides as far as an understanding of pathogenesis is concerned.
Many countries now routinely thrombolyze all patients of AIS who present within the three-hour time window and do not have any contraindication. However, many stroke units, especially those in the developing nations, are hampered by constraints of resources and lack of awareness. Feasibility of thrombolysis is still being evaluated at these centers. The hyperacute thrombolysis for stroke was started in the year 1995-1996 in India and in March 2002 at the All India Institute of Medical Center, a tertiary referral center in India. We assessed the outcome of patients treated with intravenous rtPA, including the incidence of intracerebral hemorrhage and other adverse events. The overall purpose of this paper is to report the current clinical practice of intravenous thrombolytic Padma et al.: rtPA in acute ischemic stroke therapy for acute stroke in a tertiary referral center from a developing country.
Materials and Methods
We present the detailed data of the 54 patients treated at AIIMS in whom an adequate follow-up of six months is available. All of these patients were studied prospectively.
The variables that were specifically recorded for each extensive neurological examination including the baseline � Minor stroke symptoms (NIHSS score < 4) or those that are NIH Stroke scale (NIHSS) was performed in all patients.
rapidly improving.
Other parameters noted were the demographic profile, � History of stroke in previous six weeks. stroke risk factors, baseline CT scan findings and the � Seizure at onset unless the treating physician is convinced that the neurological deficit is due to stroke and not seizure.
blood pressure measurements [ Table 1 ].
�
Previous known intracranial hemorrhage.
Potential benefits and significant risks, specifically the and exclusion criteria are shown in Table 2 . All patients � Pregnancy, lactation or parturition within the previous 30 days. had pretreatment CT scans that were read by the attending � Hypoglycemia, hyperglycemia (baseline serum glucose level neurologist together with the radiologist. Each of our must be between 50 mg% -400 mg%).
patients received 0.9 mg/Kg of intravenous rtPA up to a maximum of 90 mg, based on the estimated or actual body � Likely etiology other than acute brain ischemia. weight. Ten per cent of this calculated dose was injected � Early signs indicating infarct of more than a third of the territory as a bolus and the remainder infused over an hour.
of the middle cerebral artery.
Heparin and aspirin were withheld for the first 24h after rtPA administration in all our patients. Hypertension was during the hospital stay was noted. The peak blood treated using intravenous labetolol or intravenous pressure during rtPA administration as well as during enalapril. Occasionally, injection nitroglycerine or the first 24h after the infusion was recorded. Using the nitroprusside was required. TOAST criteria, stroke subtype was determined by the Results of follow-up CT scans or MRI scans were following classification: 1). Large artery atherosclerosis, recorded in all patients thrombolysed. The use of aspirin, clopidogrel, heparin, acitrom and antihypertensives 2). Cardio-embolic, 3). Small-vessel occlusion, 4). Stroke of other determined etiology, 5). Stroke of undetermined etiology. We obtained telephone or clinic follow-up with the patient and caregiver in all 54 cases and assessed the Barthel Activities of Daily Living Index. For analysis, we defined a good outcome as an improved NIHSS of ≥ 4 and a Barthel Index of ≥ 75%. At AIIMS, due to constraints of time and resources we deviated from the recommended NINDS protocol in excluding patients with a history of liver or renal disease and in not obtaining results of platelet counts, prothrombin time and activated partial thromboplastin time in patients prior to thrombolysis. stroke during this period. The most common reasons for disqualification from thrombolytic therapy were, exceeding the window period (38%), intracerebral hemorrhage (20%), minor or rapidly resolving symptoms (20%) and a nonstroke diagnosis (12%). Of the patients who could qualify to receive thrombolysis, 26% could not be thrombolyzed since they could not afford rtPA. The mean age of our patients was 66 years, ranging from 32 to 82. Out of the 54 patients who were thrombolysed, 31 were males. Co-morbid illnesses in the Thirty-five patients (65%) significantly improved on NIHSS at 48h (≥ 4 points) (mean change = 10; range = 4 17). At one month, 43 (79%) improved on Barthel Index (mean change = 45%). Of these, 19 (44% of the 43 patients improved; 35% of total number[54]), achieved ≥ 95% scores on Barthel Index indicating near normal functional status. Of the stroke subtypes, cardioembolic and small vessel occlusions did better than others. Of the eight patients who showed no improvement, six were lacunar strokes. One developed small frontal lobe hemorrhage and [ Table 3 ].
Results

Fifty-four patients received IV rtPA for AIS between
form of hypertension, diabetes and hypercholesterolemia recurrent stroke; one died of aspiration and eight showed were present in 44 (64.7%), 22 (41.2%) and eight (14.7%) no improvement. The mean length of follow-up after patients respectively. Additionally, atrial fibrillation was discharge was 9.5 ± 3 months. Although not part of the present in 11(20.6%), congestive heart failure in eight study protocol, modified Rankin Score (mRS) was (14.7%) and coronary artery disease in six (11.8%). There administered at the end of three months to 48 (88%) was a history of prior stroke in 10 (17.7%). The mean patients (the rest could not be directly observed). The blood pressure at admission was 156/88 mmHg and the average mRS was 1.4 (0-2). One patient developed deep mean maximum pretreatment blood pressure was 166/90 venous thrombosis of the saphenous vein and had to be mmHg. Eighteen of the 54 (32.4%) patients were smokers hospitalized for treatment. One patient developed pneumonia and recovered with therapy. The mean baseline NIHSS was 14 ± 2 (range 8-22). Using TOAST criteria, patients were classified into: large Discussion artery atherosclerotic = 13; cardioembolic = 12; small vessel occlusion = 22; other determined etiology = three;
Despite the demonstration of benefit from thrombolytic undetermined etiology = four. The mean time to reach treatment with intravenous rtPA by the NINDS trial as emergency was 2.4h (1.15-3.4h). The mean door to CT early as in 1995, this form of therapy has been relatively time was 24 min (10-47 min). The mean door to rtPA underused in developing countries. The reluctance to injection time was 26.8 min (25-67 min). The NIHSS aggressively thrombolyse patients of acute ischemic stroke scores ranged from 11 to 22 min (mean = 15.5 ± 2.7). has been attributed to several factors including delay in Patients with history of liver or renal disease or those on the arrival of the patients to stroke units, limited resources, anticoagulants were excluded. The PT, aPTT and platelet ignorance or disbelief amongst neurologists as to the count results were not obtained prior to thrombolysis. efficacy of this form of treatment and a fear of serious Early signs of infarction on CT were seen in 25/54 (46.3%) rtPA-related complications. patients. These were sulcal effacement in 11, insular We succeeded in treating 54 patients of acute ischemic ribbon sign in six and loss of gray white matter definition stroke with IV rtPA over a period of four years. Importantly, in eight. Am infarct in the follow-up CT or MRI was we were unable to thrombolyse 38% of otherwise eligible present in 53 of our 54 patients (97.1%).
patients due to delay in evaluation and treatment. Several Mean length of hospitalization in our patients was nine studies have tried to analyze the causes of such delays days. During hospital stay, antihypertensive therapy had but they have all been conducted in developed countries to be given to 44 (82.4%) patients. Antiplatelet drugs were given to all 54 patients while 10 (17.7%) received anticoagulants. No patient was given blood transfusion. Hemorrhagic conversion was noted in five (8.8%). Symptomatic intracranial hemorrhage or fatal hemorrhage did not occur in any of our patients. The mean age of patients in our study was 66 years, whereas the mean age of patients in the NINDS trial was 67 years. Advanced age increases the odds of a poor outcome after thrombolysis. [13, 14] However, post hoc analysis of the NINDS data showed rtPA to be beneficial for patients in all strata of age. As stroke increases with age, it becomes important to decide if older patients should be denied this potentially disability-avoiding therapy.
Our patients had a mean baseline NIHSS of 14 which is similar to that of patients in the NINDS rtPA trial. The stroke subtype by final diagnosis was most often, in 35.3% patients, small vessel disease. The NINDS trial and a few subsequent studies have shown that intravenous thrombolysis within the three-hour time window is similar between different stroke subtypes. therefore been recommended that extensive diagnostic evaluation to determine stroke subtypes before thrombolysis is neither required nor justified. Patients arrived in the emergency department at an average of 150 min after the symptom onset. A CT scan was performed within 22 min and intravenous rtPA was administered within an average of 27 min from the time of arrival to the emergency department respectively. A significant difference between our experience and the NINDS trial is that half of the patients randomized in the small number to draw any definite conclusions. However, the observation does reveal that in this small number of patients, hyperacute thrombolysis can be undertaken in spite of not obtaining coagulation results in carefully screened patients of AIS. A future trial needs to be undertaken with a blinded, controlled and randomized design to substantiate the above findings.
